Related references
Note: Only part of the references are listed.JAK2V617F negatively regulates p53 stabilization by enhancing MDM2 via La expression in myeloproliferative neoplasms
M. Nakatake et al.
ONCOGENE (2012)
Using Bacterial Artificial Chromosomes in Leukemia Research: The Experience at the University Cytogenetics Laboratory in Brest, France
Etienne De Braekeleer et al.
JOURNAL OF BIOMEDICINE AND BIOTECHNOLOGY (2011)
Concordance of assays designed for the quantification of JAK2V617F: a multicenter study
Eric Lippert et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2009)
Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera
Jean-Jacques Kiladjian et al.
BLOOD (2008)
JAK2 stimulates homologous recombination and genetic instability: potential implication in the heterogeneity of myeloproliferative disorders
Isabelle Plo et al.
BLOOD (2008)
Genomic instability in myeloid malignancies: Increased reactive oxygen species (ROS), DNA double strand breaks (DSBs) and error-prone repair
Annahita Sallmyr et al.
CANCER LETTERS (2008)
Clinical correlates of JAK2V617F presence or allele burden in myeloproliferative neoplasms:: a critical reappraisal
A. M. Vannucchi et al.
LEUKEMIA (2008)
Classification and diagnosis of myeloproliferative neoplasms: The 2008 World Health Organization criteria and point-of-care diagnostic algorithms
A. Tefferi et al.
LEUKEMIA (2008)
Bone marrow JAK2V617F allele burden and clinical correlates in polycythemia vera
A. Tefferi et al.
LEUKEMIA (2007)
JAK2 V617F tyrosine kinase mutation in cell lines derived from myeloproliferative disorders
H Quentmeier et al.
LEUKEMIA (2006)
Share Paper
